Gilead Sciences Inc. has taken another step in monetizing the assets garnered from its 1999 acquisition of NeXstar Pharmaceuticals Inc. for $550 million in stock. GILD believes that the liposomal technology acquired in the deal should breathe new life into a compound shelved by Glaxo Wellcome plc. GILD has reformulated the compound and says it has improved its therapeutic index